ARTERYLASTIC : First real therapeutic hope

ARTERYLASTIC : First real therapeutic hope for vascular issue in Dominant Cutis Laxa.

 

ARTERYLASTIC derives from researches lead in Lyon (France) by Dr Romain Debret. Originating from the idea that if one can make prosthetics for a joint, maybe we could make prosthestics for a failing elastin, this project is funded by the French National Agency for Research. Selected in 2018, it will start in January 2019.

The project involves 3 laboratories from the Rhône-Alpes area: Laboratory for Tissue Biology and Therapeutic Engineering (National Center for Scientific Research, Lyon), Laboratory for Hypoxia and Cardiovascular and Respiratory Physiopathologies (National Institute of Health and Medical Research, Grenoble), and Sainbiose Laboratory (National Institute of Health and Medical Research, Saint-Etienne).

The main aim of the project is to develop a synthetic elastic protein as medicine agent to improve or restore the vascular elasticity when it is failing in genetic disorders such as Cutis Laxa and Williams Syndrome, but also in non syndromic pathologies such as sleeping apneia.

This project aims to analyse the way the synthetic protein is acting and evaluate its efficiency in pertinent biological models.

The « DHERMIC » project, which preceded ARTERYLASTIC, already provided a wide set of solid data regarding the skin for the synthetic elastic protein. Recent preliminary results regarding the integration in blood vessels walls in fishes and mice are very promising.

An important part of the work will also be dedicated to the pharmacological formulation and certification to allow for the implementation of Clinical Trials at the end of the project (late 2021).

Prevalence of Cutis Laxa

Orphanet has just issued the new figures of rare disorders prevalence (number of birth/ 100 000).

https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf

Below are the figures for Cutis Laxa (PN* means at birth in Europe).

ERN-Skin

The specific European Reference Network concerning Cutis Laxa is of course included in theglobal ERNs results. Nevertheless some particular issues need to be pointed out :

  • The first training session was held in Helsinki in 2017. The second one will soon be held in Roma. These training sessions aim to train young healthcare professionals regarding specificity, difficulties, diagnostic and car for rare dermatologic disorders.
  • Conference calls are held regularly. They bring together professionals and patient representatives to work on established aims. Regarding the sub thematic group “Mendelian Connective Tissue Disorders” (MCTD), one of our first tasks will be to update the classification of the different types of Cutis Laxa.

A New Type of Cutis Laxa

In March, the American Journal of Medecine Genetics published an article showing that a mutation on the gene PTDSS1 leads to a very rare type of Cutis Laxa :  Lenz-Majewski Syndrome (LMS) . It includes Cutis Laxa with growth delay, dwarfism and intellectual delay. According to this study of 3 cases, this is a new type of Cutis Laxa that needs to be added to those already identified.

New mutations (ATP6V1E1, ATP6V1A)

ATP6V1E1 or ATP6V1A, are the new mutations recently published by a team of researchers including, among others, les nouvelles mutations publiées par une équipe de chercheurs incluant, entre autres, Mmes Gardeitchik, Mohammed, De Paepe, Malfait and Morava as well as Messrs Kornak, Wevers and Callewaert, who are researchers we are in contact with.
Those mutations can be included in Autosomal Recessive Cutis Laxa type 2 (ARCL2). They lead to Glycosylation Abnormalities (CDGs).

CLI

Scientific Talks of the 5th days of Cutis Laxa – 2016

Read all the details of the most recent findings

The scientific talks (in French and/or in English):


Dr Pascal SOMMER has isolated a molecule

With regards to therapeutic avenues, Dr Pascal SOMMER has already isolated a molecule that seems to work. There is still much to do to get this confirmed, but what progress already in 11 years !!

Identifying a new mutation (ATP6V0A2)

The study in wich Dr Zsolt URBAN took part concerning autosomal Recessive Cutis Laxa type II associated with CDG syndrom resulted in identifying a new mutation. It is a mutation on gene ATP6V0A2, leading to a loss of function of the a2 subunit of the proton prump that has an important role for fibroblasts.